Dyadic and cygnus technologies announce partnership to provide c1 hcp elisa assay to enhance quality assurance in biomanufacturing

Jupiter, fla. and leland, n.c., feb. 13, 2024 (globe newswire) -- dyadic international inc. (“dyadic”, or the “company”) (nasdaq: dyai) and cygnus technologies®, part of maravai lifesciences® (nasdaq: mrvi), announced today a strategic partnership for the quantification of host cell proteins (“hcp”) from the proprietary and patented c1-cells filamentous fungus thermothelomyces heterothallica, (formerly myceliophthora thermophila). under the terms of the partnership agreement, cygnus has developed the c1 hcp elisa kit, which will be made available to dyadic and cygnus customers.
DYAI Ratings Summary
DYAI Quant Ranking